SWOG clinical trial number
E2697
Correlation of DNA Damage Index and Clinical Response in the Context of ECOG Trial E3695: A Randomized Phase III Trial of Concurrent Biochemotherapy with Cisplatin, Vinblastine, Dacarbazine, IL-2 and Interferon Alfa-2b Versus Cisplatin, Vinblastine, Dacarbazine Alone in Patients with Metastatic Malignant Melanoma
Closed
Phase
Research committees
Melanoma
Eligibility Criteria Expand/Collapse
For patients who have been randomized to the parent protocol E3695; registration to this ancillary is NOT mandatory for randomization to E3695; specimens (blood samples) required for this protocol must arrive at the lab within 24 hours of harvest (as outlined in Appendix II).
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/EA6174
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6134
A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Research Committee(s)
Melanoma
Activated
07/13/2015
Open
Phase